1. Liraglutide Lowers the Risk for Foot Amputation in Type 2 Diabetes

A study recently published in Diabetes Care notes that patients with type 2 diabetes who took liraglutide were at a lower risk for foot amputation. Researchers completed a post hoc analysis on data collected during the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial to determine the effect of liraglutide on rates of diabetes-related foot ulcers in patients who were also at high risk for cardiovascular events. In the LEADER study, patients were randomly assigned to either an intervention arm (n=4668), receiving 1.8 mg of liraglutide a day, or a control arm (n=4672), receiving a placebo. The study continued for 5 years with an average follow-up time of 3.8 years. A diabetes-related foot ulcer was specified as a medical event of special interest, and all complications related to the ulcer were documented.

Throughout the study, the liraglutide and placebo arms had comparable occurrences of foot infections (2.3% vs 2.8%, respectively), involvement of underlying structures (1.4% vs 1.7%, respectively), peripheral revascularization (0.4% vs 0.5%, respectively), and patients experiencing at least one diabetes-related foot ulcer (3.8% vs 4.1%, respectively). The researchers did find a significant difference in the reductions of ulcer-related foot amputations between the liraglutide and the placebo arm (HR 0.65, 95% CI, 0.45-0.95; P =0.03). This decrease was even greater after the patient was on liraglutide for over a year (HR 0.55, 95% CI, 0.36, 0.84; P =0.006).

In conclusion, liraglutide may help reduce the risk of ulcer-related foot amputation among patients with type 2 diabetes who are at risk for cardiovascular events, but this correlation needs further investigation.

Read More

This newsletter is published for free distribution through the Internet for doctors, patients and public for promoting healthy lifestyles.
For enquiries info@jothydev.net.
Please visit: jothydev.net | research.jothydev.com | diabscreenkerala.net | jothydev.com/newsletter